At least according to the American Medical Association.
Shares of Vivus edged higher after the drug developer boasted of positive results of its experimental erectile dysfunction drug, putting it one step closer to tapping a $5.5 billion market.
Bill for Medicare Coverage, AMA Designation Positive for Obesity Drug Makers (ARNA) (VVUS) (OREX) - Leerink SwannStreet Insider 12:23 PM
2 Biotech Approval Outcomes That Might Affect You
StreetInsider.com Pre-Open Movers 6/19: (PLX) (CYTK) (ADBE) Higher; (OSH) (VNDA) (TTEK) Lower (more...)Street Insider 9:30 AM
Consumer Reports Says "Exercise" Rather Than Take This Drug
Obesity accounts for 21% of all health-care expenditures annually, and it's a leading risk factor for these five diseases.
MOUNTAIN VIEW, Calif. -- VIVUS, Inc. today announced that management will present an overview of the company at the following investment conference: